文献速递脑血管病

非心源性卒中后的抗血小板治疗:网络荟萃分析

Antiplatelet Therapy After Noncardioembolic Stroke.
PubMed 文献 · Stroke · 2019-06-10

结果显示阿司匹林/双嘧达莫复方、氯吡格雷及阿司匹林/氯吡格雷复方均较阿司匹林显著降低血管事件风险,但阿司匹林/氯吡格雷复方大出血风险显著更高,氯吡格雷与阿司匹林/双嘧达莫复方净临床获益相似。

要点

  • 阿司匹林/双嘧达莫复方、氯吡格雷及阿司匹林/氯吡格雷复方均较阿司匹林显著降低血管事件风险。
  • 氯吡格雷大出血和颅内出血风险显著低于阿司匹林、阿司匹林/双嘧达莫复方及阿司匹林/氯吡格雷复方。
  • 阿司匹林/氯吡格雷复方大出血风险显著高于其他方案,尤其<65岁患者超额风险更高。

核心结论

  • 非心源性卒中或TIA长期二级预防中,氯吡格雷和阿司匹林/双嘧达莫复方获结果支持,且不受患者特征影响。
  • 阿司匹林/氯吡格雷复方较其他抗血小板方案显著增加大出血风险。

研究设计与样本

  • 评估常用抗血小板药物长期(≥3个月)二级预防的效果,主要结局为严重血管事件、大出血和净临床获益。

主要发现

  • 与阿司匹林相比,阿司匹林/双嘧达莫复方显著降低血管事件风险(RRNMA-adj 0.83;95% CI 0.74-0.94)。
  • 与阿司匹林相比,氯吡格雷显著降低血管事件风险(RRNMA-adj 0.88;95% CI 0.78-0.98)。
  • 与阿司匹林相比,阿司匹林/氯吡格雷复方显著降低血管事件风险(RRNMA-adj 0.83;95% CI 0.71-0.96)。
  • 氯吡格雷与阿司匹林/双嘧达莫复方净临床获益相似(RRNMA-adj 0.99;95% CI 0.93-1.05)。
  • 阿司匹林/氯吡格雷复方较氯吡格雷单药的大出血超额风险在<65岁患者高于≥65岁患者(RRNMA-adj 3.9 vs 1.7)。

关键数值与推荐

  • 预设亚组(年龄、性别、 ethnicity、高血压、 qualifying诊断、血管类型、随机化时间)未显示治疗有效性异质性。
  • 氯吡格雷所致大出血和颅内出血显著少于阿司匹林、阿司匹林/双嘧达莫复方及阿司匹林/氯吡格雷复方。
  • 阿司匹林/氯吡格雷复方所致大出血显著多于阿司匹林、阿司匹林/双嘧达莫复方及氯吡格雷。

临床怎么用

  • 非心源性卒中或TIA长期二级预防可优先考虑氯吡格雷或阿司匹林/双嘧达莫复方。
  • 应避免常规使用阿司匹林/氯吡格雷复方进行长期二级预防,因其大出血风险显著增高。
  • 对<65岁患者使用阿司匹林/氯吡格雷复方时尤需警惕大出血超额风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical characteristics. Methods- We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results- Aspirin/dipyridamole combination (RRNMA-adj, 0.83; 95% CI, 0.74-0.94) significantly reduced the risk of vascular events compared with aspirin, as did clopidogrel (RRNMA-adj, 0.88; 95% CI, 0.78-0.98), and aspirin/clopidogrel combination (RRNMA-adj, 0.83; 95% CI, 0.71-0.96). Clopidogrel caused significantly less major bleeding and intracranial hemorrhage than aspirin, aspirin/dipyridamole combination, and aspirin/clopidogrel combination. Aspirin/clopidogrel combination caused significantly more major bleeding than aspirin, aspirin/dipyridamole combination, and clopidogrel. Net clinical benefit was similar for clopidogrel and aspirin/dipyridamole combination (RRNMA-adj, 0.99; 95% CI, 0.93-1.05). Subgroup analyses showed no heterogeneity of treatment effectiveness across prespecified subgroups. The excess risk of major bleeding associated with aspirin/clopidogrel combination compared with clopidogrel alone was higher in patients aged <65 years than it was in patients ≥65 years (RRNMA-adj, 3.9 versus 1.7). Conclusions- Results favor clopidogrel and aspirin/dipyridamole combination for long-term secondary prevention after noncardioembolic stroke or transient ischemic attack, regardless of patient characteristics. Aspirin/clopidogrel combination was associated with a significantly higher risk of major bleeding compared with other antiplatelet regimens.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Greving JP, Diener HC, Reitsma JB, et al. Antiplatelet Therapy After Noncardioembolic Stroke. Stroke. 2019. PMID: 31177983. doi:10.1161/STROKEAHA.118.024497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。